Inmune Bio plans to submit applications this year seeking regulatory approval in the U.K., the U.S., and the European Union of CORDStrom, its experimental stem cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). Inmune announced in a press release that it has formally submitted a pre-submission package…